Coherus Oncology (CHRS) Competitors $1.06 +0.01 (+0.48%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. CYRX, MBX, CMPX, ESPR, ATXS, NBTX, FULC, IVA, TNXP, and AURAShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include CryoPort (CYRX), MBX Biosciences (MBX), Compass Therapeutics (CMPX), Esperion Therapeutics (ESPR), Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Inventiva (IVA), Tonix Pharmaceuticals (TNXP), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors CryoPort MBX Biosciences Compass Therapeutics Esperion Therapeutics Astria Therapeutics Nanobiotix Fulcrum Therapeutics Inventiva Tonix Pharmaceuticals Aura Biosciences Coherus Oncology (NASDAQ:CHRS) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment. Which has more risk and volatility, CHRS or CYRX? Coherus Oncology has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Which has stronger earnings and valuation, CHRS or CYRX? Coherus Oncology has higher revenue and earnings than CryoPort. Coherus Oncology is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$272.21M0.45$28.51M$1.550.68CryoPort$228.38M1.94-$114.76M$1.336.66 Does the media prefer CHRS or CYRX? In the previous week, CryoPort had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for CryoPort and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.93 beat CryoPort's score of 0.64 indicating that Coherus Oncology is being referred to more favorably in the media. Company Overall Sentiment Coherus Oncology Positive CryoPort Positive Do insiders and institutionals have more ownership in CHRS or CYRX? 72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Comparatively, 10.1% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is CHRS or CYRX more profitable? Coherus Oncology has a net margin of 125.90% compared to CryoPort's net margin of 37.21%. Coherus Oncology's return on equity of 0.00% beat CryoPort's return on equity.Company Net Margins Return on Equity Return on Assets Coherus Oncology125.90% N/A -34.85% CryoPort 37.21%-9.79%-5.42% Do analysts rate CHRS or CYRX? Coherus Oncology currently has a consensus target price of $4.68, indicating a potential upside of 343.92%. CryoPort has a consensus target price of $12.00, indicating a potential upside of 35.44%. Given Coherus Oncology's higher probable upside, equities research analysts plainly believe Coherus Oncology is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryCryoPort beats Coherus Oncology on 10 of the 17 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.62M$3.13B$5.71B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio0.6820.9230.9125.28Price / Sales0.45232.70404.2188.50Price / Cash3.6041.5625.2228.45Price / Book-0.939.779.536.01Net Income$28.51M-$54.74M$3.26B$265.34M7 Day Performance19.85%8.37%4.66%2.89%1 Month Performance19.78%7.94%5.35%1.61%1 Year Performance-16.27%18.27%32.14%25.61% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology4.1882 of 5 stars$1.06+0.5%$4.68+343.9%-16.7%$122.62M$272.21M0.68330CYRXCryoPort3.6257 of 5 stars$8.09+7.0%$12.00+48.3%-4.4%$379.04M$228.38M6.081,186MBXMBX Biosciences2.567 of 5 stars$11.26-7.4%$37.63+234.1%N/A$376.35MN/A-2.4836CMPXCompass Therapeutics2.7111 of 5 stars$3.34+23.7%$12.67+279.2%+156.0%$373.36M$850K-8.1520Earnings ReportHigh Trading VolumeESPREsperion Therapeutics4.0359 of 5 stars$1.85-1.3%$7.00+279.4%+4.6%$370.63M$332.31M-3.77200Analyst UpgradeATXSAstria Therapeutics2.6927 of 5 stars$6.68+6.4%$29.00+334.1%-38.7%$354.41MN/A-3.5730News CoverageEarnings ReportAnalyst RevisionNBTXNanobiotix0.8197 of 5 stars$7.18-2.8%$8.00+11.5%+59.8%$353.82M$39.18M0.00100News CoverageShort Interest ↑Gap UpFULCFulcrum Therapeutics1.3605 of 5 stars$6.34-2.3%$7.57+19.4%-26.2%$351.05M$80M-5.20100IVAInventiva3.5953 of 5 stars$3.52-1.7%$10.40+195.5%+98.2%$342.47M$9.95M0.00100Positive NewsShort Interest ↓Gap UpTNXPTonix Pharmaceuticals2.6153 of 5 stars$44.97-3.3%$70.00+55.7%+15.0%$342.04M$10.09M-0.0250Earnings ReportAnalyst RevisionGap UpTrading HaltedAURAAura Biosciences1.6563 of 5 stars$6.84+0.6%$22.00+221.6%-14.7%$341.83MN/A-3.6050News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies CryoPort Alternatives MBX Biosciences Alternatives Compass Therapeutics Alternatives Esperion Therapeutics Alternatives Astria Therapeutics Alternatives Nanobiotix Alternatives Fulcrum Therapeutics Alternatives Inventiva Alternatives Tonix Pharmaceuticals Alternatives Aura Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access